You are here: Industry Insights > Market News > Granules gets US FDA nod for postpartum haemorrhage prevention drug

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

98% Bifida Ferment Lysate

rhSOD (cosmetic grade)

Recombinant humanized collagen

Recombinant Humanized Small-molecule Collagen

Recombinant Humanized Small-molecule Collagen Solution

rhSOD

Granules gets US FDA nod for postpartum haemorrhage prevention drug

financialexpressMay 21, 2018

Tag: US , FDA , postpartum haemorrhage prevention drug

Favorites

Granules India said its subsidiary has received approval from the US health regulator for Methylergonovine tablets, used for the prevention and control of postpartum haemorrhage.

In a filing to BSE, Granules India said "the US Food and Drug Administration (US FDA) has approved its abbreviated new drug applications (ANDA) for Methylergonovine 0.2 mg tablets.

The ANDA was filed by Granules Pharmaceuticals Inc., a wholly-owned subsidiary of Granules India. The approved product is the bioequivalent to the reference listed drug product Methergine 0.2 mg, it added.

Register as Visitor to CPhI China 2018!

Previous:Morepen Laboratories posts 25% rise in its net profit in FY 2017-18

Next:Alembic Pharma posts net profit of Rs 93.79 cr in Q4

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 h

PRNewswireDecember 18, 2024

Gan & Lee Pharmaceuticals is pleased to announce that the Food and Drug Administration (" FDA ") has cleared the Investigational New Drug (IND) application for GZR18 Injection to conduct a phase 2 clinical trial.

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr

PRNewswireDecember 18, 2024

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

PRNewswireDecember 19, 2024

Granules gets US FDA nod for postpartum haemorrhage prevention drug | Pharmasources.com

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

PRNewswireDecember 19, 2024

A New Premium Supplements Brand, Launched Officially on November 18th on IM8health.com

Granules gets US FDA nod for postpartum haemorrhage prevention drug

Related News

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 h

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

You may like
More>>

Granules gets US FDA nod for postpartum haemorrhage prevention drug

Related News

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 h

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

You may likeMore>>

You may like
More>>